What is the difference between ALIROCUMAB and SIMVASTATIN?

ALIROCUMAB is a PCSK9 Inhibitor and SIMVASTATIN is a Statin. They reach a similar treatment goal through different pharmacological mechanisms, which is why one may be tolerated by a patient who could not tolerate the other.

Is Praluent the same as SIMVASTATIN?

No. Praluent (ALIROCUMAB) and SIMVASTATIN (SIMVASTATIN) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, ALIROCUMAB or SIMVASTATIN?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from ALIROCUMAB to SIMVASTATIN?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

ALIROCUMAB vs SIMVASTATIN

Compare ALIROCUMAB (Praluent) and SIMVASTATIN (SIMVASTATIN) — clinical data, side effects, and patient experiences.

ALIROCUMAB

Praluent · PCSK9 Inhibitor

How it works

12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (...

Approved for

1 INDICATIONS AND USAGE PRALUENT ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death

myocardial infarction

stroke

myocardial infarction

SubcutaneousTablet

SIMVASTATIN

SIMVASTATIN, Zocor · Statin

How it works

12.1 Mechanism of Action Simvastatin is a prodrug and is hydrolyzed to its active β-hydroxyacid form, simvastatin acid, after administration. Simvastatin acid and its metabolites a...

Approved for

1 INDICATIONS AND USAGE Simvastatin tablets USP are indicated: To reduce the risk of total mortality by reducing risk of coronary heart disease death

non-fatal myocardial infarction and stroke

and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease

cerebrovascular disease

OralTablet

Quick Comparison

ALIROCUMABSIMVASTATIN

Drug Class

PCSK9 Inhibitor

Statin

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALIROCUMAB

Muscle Pain

>10%

Injection Site Pain

1-10%

Joint Pain

1-10%

Fatigue

1-10%

Limb Pain

1-10%

Diarrhea

1-10%

Headache

1-10%

Cough

0.1-1%

SIMVASTATIN

Fatigue

1-10%

Nausea

1-10%

Shortness of Breath

1-10%

Diarrhea

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Weakness

1-10%

Falls

1-10%

FDA Warnings

ALIROCUMAB

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions: hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization, have been reported with PRALUENT treatment
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT [see Contraindications (4) ]

SIMVASTATIN

5 WARNINGS AND PRECAUTIONS Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher simvastatin dosage
Chinese patients may be at higher risk for myopathy
Temporarily discontinue simvastatin in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis
Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing simvastatin dosage

Clinical Trial Data

No head-to-head clinical studies found for ALIROCUMAB vs SIMVASTATIN.

ALIROCUMAB vs SIMVASTATIN: What You Should Know

Key Differences

ALIROCUMAB is a PCSK9 Inhibitor, while SIMVASTATIN belongs to the Statin class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. ALIROCUMAB is administered via Subcutaneous, whereas SIMVASTATIN uses Oral. Route of administration can affect onset of action and patient adherence.

Safety Considerations

ALIROCUMAB carries 4 FDA warnings. SIMVASTATIN carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

EZETIMIBE AND SIMVASTATIN vs SIMVASTATIN→LOVASTATIN vs SIMVASTATIN→OCTREOTIDE vs SIMVASTATIN→Atorvastatin vs SIMVASTATIN→ALIROCUMAB vs Atorvastatin→Rosuvastatin vs SIMVASTATIN→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

ALIROCUMAB: DailyMed label · FAERS adverse events · ClinicalTrials.gov
SIMVASTATIN: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

ALIROCUMAB vs SIMVASTATIN

Compare ALIROCUMAB (Praluent) and SIMVASTATIN (SIMVASTATIN) — clinical data, side effects, and patient experiences.

ALIROCUMAB

Praluent · PCSK9 Inhibitor

How it works

12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (...

Approved for

1 INDICATIONS AND USAGE PRALUENT ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death

myocardial infarction

stroke

myocardial infarction

SubcutaneousTablet

SIMVASTATIN

SIMVASTATIN, Zocor · Statin

How it works

12.1 Mechanism of Action Simvastatin is a prodrug and is hydrolyzed to its active β-hydroxyacid form, simvastatin acid, after administration. Simvastatin acid and its metabolites a...

Approved for

1 INDICATIONS AND USAGE Simvastatin tablets USP are indicated: To reduce the risk of total mortality by reducing risk of coronary heart disease death

non-fatal myocardial infarction and stroke

and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease

cerebrovascular disease

OralTablet

Quick Comparison

ALIROCUMABSIMVASTATIN

Drug Class

PCSK9 Inhibitor

Statin

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALIROCUMAB

Muscle Pain

>10%

Injection Site Pain

1-10%

Joint Pain

1-10%

Fatigue

1-10%

Limb Pain

1-10%

Diarrhea

1-10%

Headache

1-10%

Cough

0.1-1%

SIMVASTATIN

Fatigue

1-10%

Nausea

1-10%

Shortness of Breath

1-10%

Diarrhea

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Weakness

1-10%

Falls

1-10%

FDA Warnings

ALIROCUMAB

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions: hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization, have been reported with PRALUENT treatment
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT [see Contraindications (4) ]

SIMVASTATIN

5 WARNINGS AND PRECAUTIONS Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher simvastatin dosage
Chinese patients may be at higher risk for myopathy
Temporarily discontinue simvastatin in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis
Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing simvastatin dosage

Clinical Trial Data

No head-to-head clinical studies found for ALIROCUMAB vs SIMVASTATIN.

ALIROCUMAB vs SIMVASTATIN: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.